肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2014年
4期
267-271
,共5页
吉西他滨%PF方案%鼻咽癌
吉西他濱%PF方案%鼻嚥癌
길서타빈%PF방안%비인암
Gemcitabine%PF regimen%Nasopharyngeal carcinoma
目的：探讨吉西他滨联合PF方案同期放化疗治疗72例晚期鼻咽癌的临床效果和安全性。方法将2012年2月至2012年12月我科收治的72例晚期鼻咽癌患者随机分成两组，两组接受放疗和PF方案治疗后，治疗组在此基础上给予静脉滴注吉西他滨，观察和比较两组治疗3个月后的临床疗效、生活质量的改善情况及不良反应的发生情况。结果放化疗3个月后，治疗组的近期疗效（89.2%）显著高于对照组近期疗效（71.4%），两组近期疗效相互比较差异具有统计学差异（P<0.05）；治疗组KPS改善率为78.4％，而对照组KPS改善率为60％，治疗组显著高于对照组两组KPS改善率相互比较有显著统计学差异（P<0.01），且治疗组子宫体积和肌瘤体积缩小幅度都明显优于对照组，相互比较差异有统计学意义（P<0.01）；两组患者外周血白细胞减少、血小板减少、肝肾功能损害以及脱发的发生情况相互比较有统计学差异（P<0.05）。结论吉西他滨联合PF方案同期放化疗治疗晚期鼻咽癌的近期临床疗效较单纯PF方案同期放化疗治疗晚期鼻咽癌，临床疗效确切更高，减轻毒副反应安全性更好，值得临床推广。
目的：探討吉西他濱聯閤PF方案同期放化療治療72例晚期鼻嚥癌的臨床效果和安全性。方法將2012年2月至2012年12月我科收治的72例晚期鼻嚥癌患者隨機分成兩組，兩組接受放療和PF方案治療後，治療組在此基礎上給予靜脈滴註吉西他濱，觀察和比較兩組治療3箇月後的臨床療效、生活質量的改善情況及不良反應的髮生情況。結果放化療3箇月後，治療組的近期療效（89.2%）顯著高于對照組近期療效（71.4%），兩組近期療效相互比較差異具有統計學差異（P<0.05）；治療組KPS改善率為78.4％，而對照組KPS改善率為60％，治療組顯著高于對照組兩組KPS改善率相互比較有顯著統計學差異（P<0.01），且治療組子宮體積和肌瘤體積縮小幅度都明顯優于對照組，相互比較差異有統計學意義（P<0.01）；兩組患者外週血白細胞減少、血小闆減少、肝腎功能損害以及脫髮的髮生情況相互比較有統計學差異（P<0.05）。結論吉西他濱聯閤PF方案同期放化療治療晚期鼻嚥癌的近期臨床療效較單純PF方案同期放化療治療晚期鼻嚥癌，臨床療效確切更高，減輕毒副反應安全性更好，值得臨床推廣。
목적：탐토길서타빈연합PF방안동기방화료치료72례만기비인암적림상효과화안전성。방법장2012년2월지2012년12월아과수치적72례만기비인암환자수궤분성량조，량조접수방료화PF방안치료후，치료조재차기출상급여정맥적주길서타빈，관찰화비교량조치료3개월후적림상료효、생활질량적개선정황급불량반응적발생정황。결과방화료3개월후，치료조적근기료효（89.2%）현저고우대조조근기료효（71.4%），량조근기료효상호비교차이구유통계학차이（P<0.05）；치료조KPS개선솔위78.4％，이대조조KPS개선솔위60％，치료조현저고우대조조량조KPS개선솔상호비교유현저통계학차이（P<0.01），차치료조자궁체적화기류체적축소폭도도명현우우대조조，상호비교차이유통계학의의（P<0.01）；량조환자외주혈백세포감소、혈소판감소、간신공능손해이급탈발적발생정황상호비교유통계학차이（P<0.05）。결론길서타빈연합PF방안동기방화료치료만기비인암적근기림상료효교단순PF방안동기방화료치료만기비인암，림상료효학절경고，감경독부반응안전성경호，치득림상추엄。
Objective To explore the clinical effects and safety of Gemcitabine plus PF regimen and concurrent chemo-radiotherapy for patients with advanced nasopharyngeal carcinoma. Methods A total of 72 advanced nasopharyngeal car-cinoma patients who were enrolled between February 2012 and December 2012 in our departemnt were divided randomly into two groups. All of them were treated with radiotherapy as well as PF regimen. Patients in the treating group were added with gemcitabine. After three months' treatment, observe and compare the curative effects, improvement of life quality and adverse reactions. Results After treatment for three months, the short-term clinical effect of the treating group was 89.2%, superior to that (71.4%) of the control group, with statistical difference (P<0.05). The rate of KPS improvement was 78.4%in the treating group, but was 60%in the control group, and the difference was also significantly statistical (P<0.01). There were also statistical differences in leucopenia, thrombocytopenia, liver and kidney dysfunction, hair loss between the two groups (P<0.05). Conclusion Gemcitabine plus PF regimen and concurrent chemoradiotherapy had better curative effect and greater safety for advanced nasopharyngeal carcinoma than single PF regimen with concurrent chemoradiotherapy, and this combination treatment is worth advocating in clinic.
